Analytical Data
-
Gene name
Calsequestrin 1
- Application
-
Alternative Names
PDIB1; CASQ1; Calsequestrin 1,Fast-Twitch,Skeletal Muscle; Calmitine; Calsequestrin, skeletal muscle isoform
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P31415
-
Expression Region
Gln35~Glu249
-
Molecular Weight
28kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Calsequestrin 1 (CSQ1) is a key calcium-binding protein primarily found in the sarcoplasmic reticulum of skeletal muscle cells. It plays a crucial role in calcium homeostasis, which is essential for muscle contraction and overall muscle function. The study of CSQ1 is significant due to its involvement in various muscular disorders and diseases, including myopathies and malignant hyperthermia, where disruptions in calcium signaling can lead to severe muscle dysfunction. Recombinant CSQ1 has been produced to facilitate research into its structure-function relationship, the mechanisms of calcium release, and how it interacts with other proteins in the calcium release complex. By investigating the properties of recombinant CSQ1, researchers aim to elucidate the molecular basis of muscle contraction and to develop potential therapeutic strategies for muscle-related diseases. Furthermore, recombinant CSQ1 can be utilized in functional assays to screen for drugs that might modulate calcium handling in muscle cells. Understanding CSQ1’s precise role in calcium signaling may lead to advancements in the genetic and pharmacological treatment of calcium dysregulation in muscle diseases. As such, the ongoing research into recombinant CSQ1 represents a critical intersection of molecular biology and clinical application, providing insights that may ultimately contribute to improved diagnostic and therapeutic approaches for patients suffering from muscular disorders.
